REG - Hikma Pharmaceutical - Trading Statement

Hikma PharmaceuticalsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260423:nRSW5560Ba&default-theme=true

RNS Number : 5560B  Hikma Pharmaceuticals Plc  23 April 2026

Hikma reiterates full year 2026 guidance following encouraging start to the
year

 

 

London, 23 April 2026 - Hikma Pharmaceuticals PLC (Hikma, Group), the
multinational pharmaceutical group, today provides an update on current
trading ahead of its Annual General Meeting.

 

Said Darwazah, Hikma's CEO, said:

 

"Our three businesses are performing well, supported by our differentiated
portfolio, recent product launches and our strong and growing commercial
capabilities. We continue to focus on strengthening our pipeline and today
announced the signing of a device partnership for our inhalation platform,
which will be a key growth driver for our Rx business. We are pleased with the
performance of the Group and are on track to deliver revenue and profit
growth, in line with our full year guidance and our overarching focus on
long-term sustainable profit growth."

 

Injectables

 

Our global Injectables business has started the year well and we are seeing
good demand across our geographies, supported by our broad portfolio and
strong customer relationships.

 

In the US, demand is good and we are focused on driving sustainable growth by
strengthening our supply chain, commercial execution, manufacturing network
and R&D capabilities. Our ready-to-use vancomycin bag, Tyzavan(®)(,) is
seeing accelerating demand as we gradually convert customers to this
life-saving medicine, and we continue to invest in our capacity expansion
projects, including work on our Bedford, Ohio facility, which is progressing
well.

 

Europe has had a strong start to the year, particularly in Germany and France
where we are seeing good demand for our established portfolio. MENA
Injectables is also performing well, with positive progress across our
markets.

 

We continue to expect 2026 Injectables revenue to grow in the low single
digits, with core operating margin in the range of 27% to 28%.

 

Branded

 

Our Branded business continues to perform very well, with good demand across
our portfolio and markets. We are benefiting from our broad commercial reach
and deep local market presence across MENA, as well as from our extensive
pipeline of in-licensed and internally developed products. We continue to
build on our leading positions in key therapeutic areas, including oncology,
where we benefit from a broad portfolio and dedicated local manufacturing.

 

We remain the largest pharmaceutical company by sales in the region and are
committed to ensuring continuity of supply for our patients and customers.

 

We continue to expect 2026 Branded revenue to grow in the range of 6% to 8%,
with core operating margin of around 25%.

 

Hikma Rx

 

Hikma Rx is performing in line with our expectations and demand across our
differentiated portfolio is good.  We have continued to add to this
differentiation, including the launches in February and March of authorised
generics for immediate release and extended release tapentadol in the US.

 

We are making progress in the expansion of our Columbus site to support our
growing contract manufacturing business, which will be an increasingly
important contributor to this business over the medium term.

 

R&D is critical to our growth plans and a key element of our strategy is
to invest in complex and differentiated platforms.

 

To this end, we have signed an exclusive co-development and license agreement
with an established partner for the use of their device technology in the US,
UK, Canada, EU and MENA region. This agreement will accelerate the development
of our generic Ellipta(®) programme.

 

The ongoing investment into the generic Ellipta(®) platform reflects our
focus on inhalation technologies, an area where Hikma has demonstrated
expertise, including through generic Advair Diskus(®), which remains an
important contributor to Hikma Rx revenue.

 

We continue to expect Hikma Rx revenue to be broadly flat in 2026, with core
operating margin close to 20%.

 

Others

 

To enhance our focus on our core businesses, we have taken the strategic
decision to wind down our 503B compounding business.

 

Global geopolitical environment

We are monitoring the evolving geopolitical situation in the Middle East.
Demand in the region remains robust and the Group continues to maintain
sufficient inventory levels to mitigate potential supply chain disruptions. To
date we have experienced some inflationary pressure, particularly linked to
shipping, energy and insurance costs.  We are confident we can absorb these
increased costs through a combination of strong business performance and
disciplined cost focus.

 

Group full year outlook unchanged

We continue to expect Group revenue to grow in the range of 2% to 4% and for
Group operating profit to be in the range of $720 million to $770 million in
2026.

 

Final dividend and share buyback

Subject to approval at today's Annual General Meeting, we will be paying a
final dividend of 48 cents per share. The final dividend brings the total
dividend for the full year 2025 to 84 cents per share, an increase of 5% on
2024.

 

The Group is in the process of executing a share buyback programme of up to
$250 million. Since the launch of the buyback programme on 26 February 2026 to
17 April 2026, Hikma has purchased 4,374,095 million ordinary shares at a cost
of £54.8 million ($71.5 million).

 

We will announce our interim results for the six months ended 30 June 2026 on
Thursday 6 August 2026.

 

Further information

Hikma will hold a live Q&A webinar at 9:30am BST. A recording and
transcript will be made available on the Company's website.

 

To join the webinar, please register using the following link:
https://sparklive.lseg.com/HikmaPharmaceuticals/events/18336cb5-4e47-4d98-997a-87342972ac5a
(https://sparklive.lseg.com/HikmaPharmaceuticals/events/18336cb5-4e47-4d98-997a-87342972ac5a)

 

Ellipta(®) is a registered trademark of the GSK group of companies

 

--  ENDS  --

Enquiries:

Hikma
(Investors)

 Susan Ringdal                                                                +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                             +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations

 FTI Consulting (Media)

 Ciara Martin

                                                                              +44 (0)7779 775979

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,400 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P, BBB/stable Fitch)

Forward-looking statements

Hikma cautions shareholders that any forward-looking statements or projections
made by Hikma, including those made in this announcement, are subject to risks
and uncertainties that may cause actual results to differ materially from
those projected. Such factors include, but are not limited to, those risk
factors described in the "Principal risks and uncertainties" section in
Hikma's latest Annual Report. Where included, such statements have been made
by or on behalf of Hikma in good faith based upon the knowledge and
information available to the Directors on the date of this announcement.
Accordingly, no assurance can be given that any particular expectation will be
met and Hikma's shareholders are cautioned not to place undue reliance on any
forward-looking statements. Other than in accordance with its legal or
regulatory obligations (including under the UK Market Abuse Regulation and the
UK Listing Rules and the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority), Hikma does not undertake to update any
forward-looking statements contained in this announcement to reflect any
changes in events, conditions or circumstances on which any such statement is
based or to correct any inaccuracies which may become apparent in any such
forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTDZGZDVZFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved